Search clinical trials for: large NSCLC

Total 7502 results

Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (InTRist)

Local Advanced Non-small Cell Lung Cancer

China
Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
Monte Rosa Therapeutics, Inc

Recruiting

Study of Oral MRT-2359 in Selected Cancer Patients

NSCLC | Prostate Cancer | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC Expression | HR-positive, HER2-negative Breast Cancer

United States, Canada
Maia Biotechnology

Recruiting

THIO Sequenced With Cemiplimab in Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

Poland, Australia, Bulgaria, Hungary
Pfizer

Recruiting

Crizotinib Continuation Clinical Study

NSCLC | IMT | ALCL

China, Taiwan, Japan, Russian Federation, Italy
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions

United States, United Kingdom
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Sun Yat-sen University

Recruiting

Icotinib for Completed Resected IB NSCLC With EGFR Mutation (CORIN)

Lung Neoplasms | Bronchial Neoplasms | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Terminated

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Melanoma | Non-Small Cell Lung Cancer

Italy, Australia, Belgium, Germany, Spain, Korea, Republic of, Israel, France, United States, Sweden, Poland
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Broad Solid Tumor

United States, Argentina, Australia, Canada, Chile, Japan, Romania, Singapore
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)

Melanoma | Lymphoma, Non-Hodgkin | Cervical Cancer | Multiple Myeloma | Gastric Cancer | Esophageal Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma | Non Small Cell Lung Cancer (NSCLC) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, Spain, Poland
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
Novartis Pharmaceuticals

Available

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals

Available

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Small Cell Lung Carcinoma
Novartis Pharmaceuticals

Available

Managed Access Programs for LDK378, Ceritinib

Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Adaptimmune

Active, not recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Melanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell Liposarcoma

United States, Canada
Seagen Inc.

Terminated

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Cervical Cancer | Ovarian Cancer | Peripheral T-cell Lymphoma | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Classical Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | Cutaneous Melanoma | Gastroesophageal Junction...

United States, Spain, Canada, United Kingdom, France, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
University of Florida
Monteris Medical

Terminated

LITT and Pembrolizumab in Recurrent Brain Metastasis (TORCH)

Melanoma | Primary Mediastinal Large B-Cell Lymphoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Cancer | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Brain Metastases, Adult | Renal Cell... and other conditions

United States
Mario Negri Institute for Pharmacological Research
AstraZeneca; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Active, not recruiting

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE)

Non-small Cell Lung Cancer Stage III

Italy, Spain, France
AIO-Studien-gGmbH
AstraZeneca; Celgene

Completed

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION)

Carcinoma, Non-Small-Cell Lung | Non Small Cell Lung Cancer | Metastatic Lung Cancer | Lung Adenocarcinoma Metastatic | Large Cell Lung Carcinoma Metastatic

Germany
Karyopharm Therapeutics Inc

Suspended

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States
M.D. Anderson Cancer Center
Varian Medical Systems

Completed

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Lung Cancer

United States
Stanford University

Completed

Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

Non-small Cell Lung Cancer (NSCLC)

United States, Japan, Canada
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Swiss Group for Clinical Cancer Research

Completed

Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

Switzerland
Hoffmann-La Roche

Terminated

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma

United States, Australia, Germany, Korea, Republic of, New Zealand
Ariad Pharmaceuticals

Completed

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)

Carcinoma | Lung Cancer | Non-small Cell Lung Cancer | Advanced Malignancies

United States, Canada, Germany, Spain, Taiwan, Korea, Republic of, Switzerland, Hong Kong, Singapore, Italy, Sweden, United Kingdom, France, Netherlands, Denmark, Australia, Norway, Austria, Luxembourg
GlaxoSmithKline
Health Research Associates, Inc.

Completed

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

Neoplasms

United States
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Non-small Cell Lung Cancer

China, Taiwan, Belgium, Netherlands, Spain, Germany, Singapore, Italy, Japan, Australia, Israel, Korea, Republic of, Thailand, France
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC (FORCE)

Metastatic Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Lung Adenocarcinoma Metastatic | Large Cell Lung Carcinoma Metastatic

Germany
Novartis Pharmaceuticals

Withdrawn

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Non-small Cell Lung Carcinoma (NSCLC)
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
NewLink Genetics Corporation
National Cancer Institute (NCI)

Completed

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Adenocarcinoma of Lung | Non-small Cell Carcinoma | Squamous Cell Carcinoma | Large Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Carcinoma, Non-Small Cell Lung | Carcinoma, Large Cell

United States
M.D. Anderson Cancer Center
United States Department of Defense; Genentech, Inc.

Completed

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer

United States
The First Affiliated Hospital of Soochow University

Completed

The Affection of Two Chest Management for Enhanced Recovery Program After Video-assisted Thoracoscopic Lobectomy.

Chest Tube

China
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Lung Cancer

Switzerland
Celgene

Completed

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

Adenocarcinoma | Carcinoma | Non-Small Cell Lung Cancer | Carcinoma, Large Cell | Squamous Cell Carcinoma | Lung Neoplasm

United States
Sunesis Pharmaceuticals

Completed

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Non-small-cell Lung Cancer

United States
New Mexico Cancer Care Alliance

Terminated

IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors

Recurrent Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Completed

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer
Pfizer

Terminated

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Adenosquamous | Carcinoma, Large Cell

United States, Bulgaria, Canada, Ukraine, Greece, Austria, France, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, Finland, Hungary, Taiwan, Italy, Japan, Australia, Germany, Brazil, India, Puerto Rico, Czech Republic, ... and more
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
Korean South West Oncology Group

Unknown

A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment

Carcinoma, Non-Small-Cell Lung | Carcinoma, Large Cell | Carcinoma, Squamous

Korea, Republic of

Search clinical trials for: large NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations